Rapid Micro Biosystems secures $60m investment

摘要

Rapid Micro Biosystems (RMB) has secured US $60 million in equity financing led by new investors Bain Capital Life Sciences and Xeraya Capital. A US-based company, RMB provides automated, growth-based, rapid microbial detection technology for the healthcare product manufacturing sector, including the processing of pharmaceuticals, biologies, biotech products, medical devices and personal care products. The new funding round includes a commitment from another new investor, Asahi Kasei Medical, along with continued participation by Longitude Capital, Quaker Partners, TVM Capital and Richard K. Mellon and Sons. The funding will be used to accelerate global commercial expansion, operational capability and product innovation of RMB's rapid microbial detection technology. Growth Direct by RBM, has been designed to detect contamination more quickly, delivering economic benefits to manufacturers while improving their quality control operations, securing data integrity processes and reducing operational risks.